{"id":"apo-latanoprost","safety":{"commonSideEffects":[{"rate":"5–15","effect":"Increased iris pigmentation"},{"rate":"25–35","effect":"Conjunctival hyperemia"},{"rate":"5–10","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5–10","effect":"Eye irritation/discomfort"},{"rate":"5–10","effect":"Darkening of periocular skin"}]},"_chembl":{"chemblId":"CHEMBL1051","moleculeType":"Small molecule","molecularWeight":"432.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Latanoprost mimics the action of prostaglandin F2α by activating F-prostanoid receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the unconventional (uveoscleral) pathway, reducing intraocular pressure without significantly affecting aqueous humor production. The drug is administered as a topical ophthalmic solution.","oneSentence":"Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:28.637Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT02792803","phase":"PHASE4","title":"A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma","status":"UNKNOWN","sponsor":"Dr. David Yan","startDate":"2015-09","conditions":"POAG, Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["02296527"],"phase":"marketed","status":"active","brandName":"Apo-Latanoprost","genericName":"Apo-Latanoprost","companyName":"Dr. David Yan","companyId":"dr-david-yan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apo-Latanoprost is a small molecule that acts as a prostanoid FP receptor agonist. It is used to treat conditions such as Primary Open Angle Glaucoma (POAG) and Ocular Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}